ChromaDex (NASDAQ:CDXC) Downgraded to Buy Rating by StockNews.com

ChromaDex (NASDAQ:CDXC) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Tuesday.

Several other equities analysts have also issued reports on CDXC. HC Wainwright raised their price target on ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. Roth Mkm increased their price objective on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th.

ChromaDex Stock Performance

CDXC stock opened at $5.70 on Tuesday. The company has a market capitalization of $435.38 million, a PE ratio of 570.57 and a beta of 2.16. ChromaDex has a one year low of $1.36 and a one year high of $7.97. The company’s 50 day moving average price is $5.82 and its two-hundred day moving average price is $4.05.

ChromaDex (NASDAQ:CDXC) last issued its earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. The company had revenue of $25.58 million for the quarter, compared to analysts’ expectations of $23.70 million. During the same quarter last year, the company earned ($0.01) EPS. On average, research analysts predict that ChromaDex will post 0.04 EPS for the current year.

Insider Transactions at ChromaDex

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the sale, the director now owns 244,179 shares of the company’s stock, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 9.64% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ChromaDex

Several institutional investors and hedge funds have recently modified their holdings of CDXC. OneDigital Investment Advisors LLC increased its position in shares of ChromaDex by 5.5% during the third quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company’s stock valued at $217,000 after buying an additional 3,097 shares during the period. MetLife Investment Management LLC boosted its position in ChromaDex by 39.3% during the 3rd quarter. MetLife Investment Management LLC now owns 18,114 shares of the company’s stock valued at $66,000 after acquiring an additional 5,115 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of ChromaDex by 75.4% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 19,732 shares of the company’s stock worth $72,000 after acquiring an additional 8,485 shares during the period. Merriman Wealth Management LLC bought a new position in shares of ChromaDex in the 2nd quarter worth approximately $32,000. Finally, FMR LLC purchased a new position in shares of ChromaDex in the 3rd quarter valued at approximately $55,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.